4.7 Article

Cryptic activation of an Irf8 enhancer governs cDC1 fate specification

期刊

NATURE IMMUNOLOGY
卷 20, 期 9, 页码 1161-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41590-019-0450-x

关键词

-

资金

  1. Howard Hughes Medical Institute
  2. US National Institutes of Health [NIH: F30 DK108498, K08 CA230188, P50 HG007735, R01 AI106352, R01 DK097317]
  3. National Science Foundation [DGE-1745038]
  4. Parker Institute for Cancer Immunotherapy
  5. Boehringer Ingelheim
  6. Career Award for Medical Scientists from the Burroughs Wellcome Fund
  7. National Cancer Institute's Cancer Center Support grant [P30 CA91842]
  8. Institute of Clinical and Translational Sciences/Clinical and Translational Science Award from the National Center for Research Resources (NCRR), a component of the NIH [UL1TR000448]
  9. NIH Roadmap for Medical Research

向作者/读者索取更多资源

Induction of the transcription factor Irf8 in the common dendritic cell progenitor (CDP) is required for classical type 1 dendritic cell (cDC1) fate specification, but the mechanisms controlling this induction are unclear. In the present study Irf8 enhancers were identified via chromatin profiling of dendritic cells and CRISPR/Cas9 genome editing was used to assess their roles in Irf8 regulation. An enhancer 32 kilobases (kb) downstream of the Irf8 transcriptional start site (+32-kb Irf8) that was active in mature cDC1s was required for the development of this lineage, but not for its specification. Instead, a +41-kb Irf8 enhancer, previously thought to be active only in plasmacytoid dendritic cells, was found to also be transiently accessible in cDC1 progenitors, and deleting this enhancer prevented the induction of Irf8 in CDPs and abolished cDC1 specification. Thus, cryptic activation of the +41-kb Irf8 enhancer in dendritic cell progenitors is responsible for cDC1 fate specification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据